Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of -102.47% is 971% below its 5-year average of -9.57%, around the middle of its 5-year range (-475.61%–60.00%).
42.05% above its 12-month average of -176.82%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): -66.67%.
GROSS MARGIN
-102.47%
GROSS MARGIN AVG TTM
-176.82%
GROSS MARGIN AVG 3Y
-68.39%
GROSS MARGIN AVG 5Y
-9.57%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+42.05%
CURRENT VS 3Y AVG
-49.84%
CURRENT VS 5Y AVG
-970.68%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-347.63%
vs the sector median at left
Sera Prognostics, Inc.
Market Cap
$78.29M
Gross Margin
-102.47%
TTM Avg
-176.82%
3Y Avg
-68.39%
5Y Avg
-9.57%
Market Cap
$78.07M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$78.59M
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
50.00%
5Y Avg
38.04%
Market Cap
$77.54M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$79.61M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$76.74M
Gross Margin
41.76%
TTM Avg
36.53%
3Y Avg
27.69%
5Y Avg
15.34%
Market Cap
$80.30M
Gross Margin
-736.46%
TTM Avg
-368.23%
3Y Avg
-290.99%
5Y Avg
-1574.61%
Market Cap
$75.95M
Gross Margin
66.34%
TTM Avg
59.91%
3Y Avg
56.70%
5Y Avg
58.64%
Market Cap
$80.80M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sera Prognostics, Inc. (SERA) | $78.29M | -102.47% | -176.82% | -68.39% | -9.57% |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.07M | 100.00% | 100.00% | 100.00% | 100.00% |
| vTv Therapeutics Inc. (VTVT)vs › | $78.59M | 0.00% | 50.00% | 50.00% | 38.04% |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $77.54M | 100.00% | 100.00% | 100.00% | 100.00% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $79.61M | 0.00% | 0.00% | 0.00% | 0.00% |
| Outset Medical, Inc. (OM)vs › | $76.74M | 41.76% | 36.53% | 27.69% | 15.34% |
| Humacyte, Inc. (HUMA)vs › | $80.30M | -736.46% | -368.23% | -290.99% | -1574.61% |
| SkinHealth Systems Inc. (SKIN)vs › | $75.95M | 66.34% | 59.91% | 56.70% | 58.64% |
| Citius Oncology, Inc. (CTOR)vs › | $80.80M | 0.00% | 0.00% | 0.00% | 0.00% |
| Nutriband Inc. (NTRB)vs › | $81.20M | 33.14% | 30.24% | 34.48% | 35.28% |
Gross Margin
-102.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | -66.67% |
| 2026-03-31 | -200.00% |
| 2025-12-31 | -320.00% |
| 2025-09-30 | -156.25% |
| 2025-06-30 | -141.18% |
| 2025-03-31 | -5.26% |
| 2024-12-31 | -33.33% |
| 2024-09-30 | 55.17% |
| 2024-06-30 | 16.67% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | -475.61% |
| 2023-09-30 | -4.76% |
| 2023-06-30 | 34.96% |
| 2023-03-31 | 38.00% |
| 2022-12-31 | 9.23% |
| 2022-09-30 | 33.33% |
| 2022-06-30 | 28.21% |
| 2022-03-31 | 47.37% |
| 2021-12-31 | 46.15% |
| 2021-09-30 | 56.52% |
| 2021-06-30 | 60.00% |
| 2021-03-31 | 61.54% |
| 2020-12-31 | 50.00% |
| 2020-09-30 | 40.00% |
| 2020-06-30 | 66.67% |
| 2020-03-31 | 62.50% |
